Journal of Neuroimmunology, Vol. 129 (1-2) (2002) pp. 197-204
C.L.A. Mann a, M.B. Davies a, V.L. Stevenson b, S.M. Leary b, M.D. Boggild c, C. Ko Ko a, P.W. Jones d, A.A. Fryer e, R.C. Strange e, A.J. Thompson b and C.P. Hawkins a
a Keele Multiple Sclerosis Research Group, Department of Neurology, North Staffordshire Hospital, Stoke on Trent, Staffordshire, England, ST4 7LN, UK
b Institute of Neurology, Queen Square, University College London, London, UK
c Walton Centre for Neurology and Neurosurgery, Liverpool, UK
d Department of Mathematics, Keele University, England, UK
e Centre for Molecular and Cell Medicine, School of Postgraduate Medicine, Keele University, Keele, UK
We studied the association between clinical outcome in MS and allelic variants single nucleotide polymorphisms (SNPs) of interleukin-1 (IL-1), IL-1 and a variable number tandem repeat (VNTR) in IL-1 receptor antagonist (IL-1RN).
A total of 377 patients with MS were studied.
Significant associations between IL-1 genotypes and clinical outcome were found using logistic regression after correction for gender, onset age and disease duration.
The same trends were subsequently demonstrated in a second independent group of 67 primary progressive patients.
Our results suggest that genetically determined immunomodulation mediated by IL-1 influences long-term prognosis in multiple sclerosis (MS).
© 2002 Elsevier Science B.V.